Use this URL to cite or link to this record in EThOS:
Title: An investigation of serological tumour markers in epithelial ovarian cancer
Author: Fisken, Jane
Awarding Body: University of Edinburgh
Current Institution: University of Edinburgh
Date of Award: 1992
Availability of Full Text:
Access from EThOS:
Full text unavailable from EThOS. Please try the link below.
Access from Institution:
Epithelial ovarian cancer (EOC) accounts for over 80% of ovarian carcinomas. More than two-thirds of patients present with metastatic disease resulting in a poor five year survival of 25&37. Surgery is the mainstay of treatment; subsequently the majority of patients receive platinum based chemotherapy regimes. Although chemotherapy may improve progression free survival, it has little impact on overall survival. CA125 has an established role in monitoring response to chemotherapy and providing a lead time to clinical relapse. Its value in prognosis, however, requires clarification. Not all patients express CA125, therefore complementary tumour markers have been intensively sought. The most promising antigenic molecule to date is polymorphic epithelial mucin, against which numerous monoclonal antibodies have been raised. Using several of these antibodies, this thesis investigated the role of the following mucin antigens in EOC; HMFG2, CA153, CA724, and CA199. In addition, tumour-associated trypsin inhibitor (TATI) and p185, the glycoprotein encoded for by the neu (c erb B2/HER-2) oncogene, were evaluated. Double-determinant immunoassay was the most common method of antigen quantitation. An ELISA was developed for HMFG2 'in-house', while the remaining markers were measured using commercial assay kits. 1237 blood samples were collected post-operatively from April 1984 to July 1989 from 250 EOC patients. After retrospective clinical documentation, a database consisting of each patient's case history and serial serum marker levels was developed in collaboration with Unilever Research to perform statistical analyses. CA125 was elevated in a greater proportion of patients with all FIGO stages and histological tumour types than all other markers. Whilst serum p185 was elevated in very few patients, there were insufficient data (the major restriction being cost) to assess the clinical correlates of CA153, CA199, CA724 and TATI. HMFG2 showed most promise and was therefore evaluated in more detail.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID:  DOI: Not available